메뉴 건너뛰기




Volumn 119, Issue 21, 2013, Pages 3761-3768

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: Developing criteria to continue therapy beyond RECIST progression

Author keywords

computed tomography; epidermal growth factor receptor tyrosine kinase inhibitors; lung cancer; tumor growth rate; tumor volume

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

EID: 84886091897     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28290     Document Type: Article
Times cited : (43)

References (53)
  • 1
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
    • (2004) Science. , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Janne, P.A.2    Lee, J.C.3
  • 2
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
    • (2004) N Engl J Med. , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 3
    • 4444344330 scopus 로고    scopus 로고
    • EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    • Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101: 13306-13311.
    • (2004) Proc Natl Acad Sci USA. , vol.101 , pp. 13306-13311
    • Pao, W.1    Miller, V.2    Zakowski, M.3
  • 4
    • 33846483745 scopus 로고    scopus 로고
    • EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: Retro- and prospective observations in non-small-cell lung cancer
    • van Zandwijk N, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol. 2007; 18: 99-103.
    • (2007) Ann Oncol. , vol.18 , pp. 99-103
    • Van Zandwijk, N.1    Mathy, A.2    Boerrigter, L.3
  • 5
    • 45149084723 scopus 로고    scopus 로고
    • First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    • Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008; 26: 2442-2449.
    • (2008) J Clin Oncol. , vol.26 , pp. 2442-2449
    • Sequist, L.V.1    Martins, R.G.2    Spigel, D.3
  • 6
    • 33746034167 scopus 로고    scopus 로고
    • Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    • Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12: 3908-3914.
    • (2006) Clin Cancer Res. , vol.12 , pp. 3908-3914
    • Jackman, D.M.1    Yeap, B.Y.2    Sequist, L.V.3
  • 7
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S,. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
    • (2009) N Engl J Med. , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 8
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
    • (2010) N Engl J Med. , vol.362 , pp. 2380-2388
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3
  • 9
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
    • Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735-742.
    • (2011) Lancet Oncol. , vol.12 , pp. 735-742
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3
  • 10
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
    • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
    • (2012) Lancet Oncol. , vol.13 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3
  • 11
    • 18244371651 scopus 로고    scopus 로고
    • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [serial online]
    • Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [serial online]. PloS Med. 2005; 2: e73.
    • (2005) PloS Med. , vol.2
    • Pao, W.1    Miller, V.A.2    Politi, K.A.3
  • 12
    • 34249075147 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 1039-1043.
    • (2007) Science. , vol.316 , pp. 1039-1043
    • Engelman, J.A.1    Zejnullahu, K.2    Mitsudomi, T.3
  • 13
    • 13844317894 scopus 로고    scopus 로고
    • EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    • Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-792.
    • (2005) N Engl J Med. , vol.352 , pp. 786-792
    • Kobayashi, S.1    Boggon, T.J.2    Dayaram, T.3
  • 14
    • 79953118839 scopus 로고    scopus 로고
    • Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors [serial online]
    • 75ra26
    • Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors [serial online]. Sci Transl Med. 2011; 23: 3:75ra26.
    • (2011) Sci Transl Med. , vol.23 , pp. 3
    • Sequist, L.V.1    Waltman, B.A.2    Dias-Santagata, D.3
  • 15
    • 79952259564 scopus 로고    scopus 로고
    • Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    • Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011; 17: 1169-1180.
    • (2011) Clin Cancer Res. , vol.17 , pp. 1169-1180
    • Arcila, M.E.1    Oxnard, G.R.2    Nafa, K.3
  • 16
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
    • (2000) J Natl Cancer Inst. , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 17
    • 57849117384 scopus 로고    scopus 로고
    • New Response Evaluation Criteria in Solid Tumors: Revised RECIST guideline (version 1.1)
    • Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
    • (2009) Eur J Cancer. , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 18
    • 77955591119 scopus 로고    scopus 로고
    • Pictorial review of the new Response Evaluation Criteria in Solid Tumors: Revised RECIST guideline version 1.1 - What oncologists want to know and what radiologists need to know
    • Nishino M, Jagannathan JP, Ramaiya N, et al. Pictorial review of the new Response Evaluation Criteria in Solid Tumors: revised RECIST guideline version 1.1-What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010; 195: 281-229.
    • (2010) AJR Am J Roentgenol. , vol.195 , pp. 281-229
    • Nishino, M.1    Jagannathan, J.P.2    Ramaiya, N.3
  • 19
    • 73149092567 scopus 로고    scopus 로고
    • Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
    • Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412-7420.
    • (2009) Clin Cancer Res. , vol.15 , pp. 7412-7420
    • Wolchok, J.D.1    Hoos, A.2    O'Day, S.3
  • 20
    • 84859118421 scopus 로고    scopus 로고
    • Personalized tumor response assessment in the era of molecular medicine: Cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST
    • Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol. 2012; 198: 737-745.
    • (2012) AJR Am J Roentgenol. , vol.198 , pp. 737-745
    • Nishino, M.1    Jagannathan, J.P.2    Krajewski, K.M.3
  • 22
    • 34249085905 scopus 로고    scopus 로고
    • Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    • Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753-1759.
    • (2007) J Clin Oncol. , vol.25 , pp. 1753-1759
    • Choi, H.1    Charnsangavej, C.2    Faria, S.C.3
  • 23
    • 34548853993 scopus 로고    scopus 로고
    • Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
    • Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007; 13: 5150-5155.
    • (2007) Clin Cancer Res. , vol.13 , pp. 5150-5155
    • Riely, G.J.1    Kris, M.G.2    Zhao, B.3
  • 24
    • 74949110711 scopus 로고    scopus 로고
    • Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    • Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010; 28: 357-360.
    • (2010) J Clin Oncol. , vol.28 , pp. 357-360
    • Jackman, D.1    Pao, W.2    Riely, G.J.3
  • 25
    • 84873166606 scopus 로고    scopus 로고
    • Radiographic response assessment and therapeutic treatment decisions at the time of RECIST progression in EGFR-mutant NSCLC
    • Nishino M, Cardarella S, Dahlberg SE, et al. Radiographic response assessment and therapeutic treatment decisions at the time of RECIST progression in EGFR-mutant NSCLC. Lung Cancer. 2013; 79: 283-288.
    • (2013) Lung Cancer. , vol.79 , pp. 283-288
    • Nishino, M.1    Cardarella, S.2    Dahlberg, S.E.3
  • 26
    • 84867901891 scopus 로고    scopus 로고
    • Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: A retrospective analysis for Japanese patients with activating EGFR mutations
    • Nishie K, Kawaguchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol. 2012; 7: 1722-1727.
    • (2012) J Thorac Oncol. , vol.7 , pp. 1722-1727
    • Nishie, K.1    Kawaguchi, T.2    Tamiya, A.3
  • 27
    • 33846651571 scopus 로고    scopus 로고
    • Lung cancer: Computerized quantification of tumor response - Initial results
    • Zhao B, Schwartz LH, Moskowitz CS, et al. Lung cancer: computerized quantification of tumor response-initial results. Radiology. 2006; 241: 892-898.
    • (2006) Radiology. , vol.241 , pp. 892-898
    • Zhao, B.1    Schwartz, L.H.2    Moskowitz, C.S.3
  • 28
    • 67650085792 scopus 로고    scopus 로고
    • Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer
    • Zhao B, James LP, Moskowitz CS, et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009; 252: 263-272.
    • (2009) Radiology. , vol.252 , pp. 263-272
    • Zhao, B.1    James, L.P.2    Moskowitz, C.S.3
  • 29
    • 77956126688 scopus 로고    scopus 로고
    • Change in lung tumor volume as a biomarker of treatment response: A critical review of the evidence
    • Mozley PD, Schwartz LH, Bendtsen C, et al. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol. 2010; 21: 1751-1755.
    • (2010) Ann Oncol. , vol.21 , pp. 1751-1755
    • Mozley, P.D.1    Schwartz, L.H.2    Bendtsen, C.3
  • 30
    • 84862915437 scopus 로고    scopus 로고
    • Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer
    • Mozley PD, Bendtsen C, Zhao B, et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol. 2012; 5: 19-25.
    • (2012) Transl Oncol. , vol.5 , pp. 19-25
    • Mozley, P.D.1    Bendtsen, C.2    Zhao, B.3
  • 31
    • 78649905395 scopus 로고    scopus 로고
    • CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of emerging clinical tool
    • Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of emerging clinical tool. Acad Radiol. 2011; 18: 54-62.
    • (2011) Acad Radiol. , vol.18 , pp. 54-62
    • Nishino, M.1    Guo, M.2    Jackman, D.M.3
  • 32
    • 39749138382 scopus 로고    scopus 로고
    • Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy
    • Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 70: 1039-1044.
    • (2008) Int J Radiat Oncol Biol Phys. , vol.70 , pp. 1039-1044
    • Dehing-Oberije, C.1    De Ruysscher, D.2    Van Der Weide, H.3
  • 33
    • 79952701039 scopus 로고    scopus 로고
    • Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy
    • Alexander BM, Othus M, Caglar HB, Allen AM,. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011; 79: 1381-1387.
    • (2011) Int J Radiat Oncol Biol Phys. , vol.79 , pp. 1381-1387
    • Alexander, B.M.1    Othus, M.2    Caglar, H.B.3    Allen, A.M.4
  • 34
    • 79955421128 scopus 로고    scopus 로고
    • Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer
    • Kozak MM, Murphy JD, Schipper ML, et al. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6: 920-906.
    • (2011) J Thorac Oncol. , vol.6 , pp. 920-906
    • Kozak, M.M.1    Murphy, J.D.2    Schipper, M.L.3
  • 35
    • 84880924699 scopus 로고    scopus 로고
    • Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI
    • [published online ahead of print June 19, 2013]
    • Nishino M, Dahlberg SE, Cardarella S, et al. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI [published online ahead of print June 19, 2013]. J Thorac Oncol. 2013.
    • (2013) J Thorac Oncol.
    • Nishino, M.1    Dahlberg, S.E.2    Cardarella, S.3
  • 36
    • 0003293418 scopus 로고
    • On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies
    • Gompertz B,. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Phil Trans R Soc (Lond). 1825; 115: 513.
    • (1825) Phil Trans R Soc (Lond). , vol.115 , pp. 513
    • Gompertz, B.1
  • 37
    • 0037732947 scopus 로고    scopus 로고
    • Gompertzian growth pattern correlated with phenotypic organization of colon carcinoma, malignant glioma and non-small cell lung carcinoma cell lines
    • Castro MA, Klamt F, Grieneisen VA, Grivicich I, Moreira JC,. Gompertzian growth pattern correlated with phenotypic organization of colon carcinoma, malignant glioma and non-small cell lung carcinoma cell lines. Cell Prolif. 2003; 36: 65-73.
    • (2003) Cell Prolif. , vol.36 , pp. 65-73
    • Castro, M.A.1    Klamt, F.2    Grieneisen, V.A.3    Grivicich, I.4    Moreira, J.C.5
  • 38
    • 0024330777 scopus 로고
    • An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data
    • Demicheli R, Foroni R, Ingrosso A, Pratesi G, Soranzo C, Tortoreto M,. An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data. Cancer Res. 1989; 49: 6543-6546.
    • (1989) Cancer Res. , vol.49 , pp. 6543-6546
    • Demicheli, R.1    Foroni, R.2    Ingrosso, A.3    Pratesi, G.4    Soranzo, C.5    Tortoreto, M.6
  • 39
    • 0017736818 scopus 로고
    • Growth curve of an experimental solid tumor following radiotherapy
    • Norton L, Simon R,. Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst. 1977; 58: 1735-1741.
    • (1977) J Natl Cancer Inst. , vol.58 , pp. 1735-1741
    • Norton, L.1    Simon, R.2
  • 40
    • 0016696714 scopus 로고
    • Solid tumor models for the assessment of different treatment modalities. I. Radiation-induced changes in growth rate characteristics of a solid tumor model
    • Looney WB, Trefil JS, Schaffner JC, Kovacs CJ, Hopkins HA,. Solid tumor models for the assessment of different treatment modalities. I. Radiation-induced changes in growth rate characteristics of a solid tumor model. Proc Natl Acad Sci U S A. 1975; 72: 2662-2666.
    • (1975) Proc Natl Acad Sci U S A , vol.72 , pp. 2662-2666
    • Looney, W.B.1    Trefil, J.S.2    Schaffner, J.C.3    Kovacs, C.J.4    Hopkins, H.A.5
  • 41
    • 0017258972 scopus 로고
    • Solid tumor models for the assessment of different treatment modalities: Systematics of response to radiotherapy and chemotherapy
    • Looney WB, Trefil JS, Schaffner JG, Kovacs CJ, Hopkins HA,. Solid tumor models for the assessment of different treatment modalities: systematics of response to radiotherapy and chemotherapy. Proc Natl Acad Sci U S A. 1976; 73: 818-822.
    • (1976) Proc Natl Acad Sci U S A. , vol.73 , pp. 818-822
    • Looney, W.B.1    Trefil, J.S.2    Schaffner, J.G.3    Kovacs, C.J.4    Hopkins, H.A.5
  • 42
    • 0017395129 scopus 로고
    • Solid tumor models for assessment of different treatment modalities: Therapeutic strategy for sequential chemotherapy with radiotherapy
    • Looney WB, Trefil JS, Hopkins HA, Kovacs CJ, Ritenour R, Schaffner JG,. Solid tumor models for assessment of different treatment modalities: therapeutic strategy for sequential chemotherapy with radiotherapy. Proc Natl Acad Sci U S A. 1977; 74: 1983-1987.
    • (1977) Proc Natl Acad Sci U S A. , vol.74 , pp. 1983-1987
    • Looney, W.B.1    Trefil, J.S.2    Hopkins, H.A.3    Kovacs, C.J.4    Ritenour, R.5    Schaffner, J.G.6
  • 43
    • 78650390328 scopus 로고    scopus 로고
    • Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib
    • Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010; 16: 5873-5882.
    • (2010) Clin Cancer Res. , vol.16 , pp. 5873-5882
    • Heon, S.1    Yeap, B.Y.2    Britt, G.J.3
  • 44
    • 84865076205 scopus 로고    scopus 로고
    • The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations
    • Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012; 18: 4406-4414.
    • (2012) Clin Cancer Res. , vol.18 , pp. 4406-4414
    • Heon, S.1    Yeap, B.Y.2    Lindeman, N.I.3
  • 45
    • 76649134591 scopus 로고    scopus 로고
    • Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma [abstract]
    • 15. Abstract 8065
    • Jackman DM, Cioffredi LA, Lindeman N, et al. Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma [abstract]. J Clin Oncol. 2009; 27:15(suppl). Abstract 8065.
    • (2009) J Clin Oncol. , vol.27 , Issue.SUPPL
    • Jackman, D.M.1    Cioffredi, L.A.2    Lindeman, N.3
  • 46
    • 33947504732 scopus 로고    scopus 로고
    • Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer
    • Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007; 25: 760-766.
    • (2007) J Clin Oncol. , vol.25 , pp. 760-766
    • Jackman, D.M.1    Yeap, B.Y.2    Lindeman, N.I.3
  • 47
    • 2642539590 scopus 로고    scopus 로고
    • Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "iressa") on an expanded access study
    • Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer. 2004; 44: 221-230.
    • (2004) Lung Cancer. , vol.44 , pp. 221-230
    • Janne, P.A.1    Gurubhagavatula, S.2    Yeap, B.Y.3
  • 48
    • 0020333131 scopus 로고
    • Random-effects models for longitudinal data
    • Laird NM, Ware JH,. Random-effects models for longitudinal data. Biometrics. 1982; 38: 963-974.
    • (1982) Biometrics. , vol.38 , pp. 963-974
    • Laird, N.M.1    Ware, J.H.2
  • 49
    • 84873364068 scopus 로고    scopus 로고
    • Tumor assessment criteria in phase i trials: Beyond RECIST [letter]
    • Levy A, Hollebecque A, Ferte C, et al. Tumor assessment criteria in phase I trials: beyond RECIST [letter]. J Clin Oncol. 2013; 31: 395.
    • (2013) J Clin Oncol. , vol.31 , pp. 395
    • Levy, A.1    Hollebecque, A.2    Ferte, C.3
  • 50
    • 80755139581 scopus 로고    scopus 로고
    • Tumour growth rates and RECIST criteria in early drug development
    • Gomez-Roca C, Koscielny S, Ribrag V, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer. 2011; 47: 2512-2516.
    • (2011) Eur J Cancer. , vol.47 , pp. 2512-2516
    • Gomez-Roca, C.1    Koscielny, S.2    Ribrag, V.3
  • 51
    • 84859871183 scopus 로고    scopus 로고
    • Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth
    • Stein WD, Wilkerson J, Kim ST, et al. Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res. 2012; 18: 2374-2381.
    • (2012) Clin Cancer Res. , vol.18 , pp. 2374-2381
    • Stein, W.D.1    Wilkerson, J.2    Kim, S.T.3
  • 52
    • 79951826832 scopus 로고    scopus 로고
    • Tumor regression and growth rates determined in 5 intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy
    • Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in 5 intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res. 2011; 17: 907-917.
    • (2011) Clin Cancer Res. , vol.17 , pp. 907-917
    • Stein, W.D.1    Gulley, J.L.2    Schlom, J.3
  • 53
    • 84867062177 scopus 로고    scopus 로고
    • ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) [abstract]
    • Abstract TPS7614
    • Park K, Tsai CM, Ahn M, et al. ASPIRATION: phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract TPS7614.
    • (2012) J Clin Oncol. , vol.30 , Issue.SUPPL
    • Park, K.1    Tsai, C.M.2    Ahn, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.